Effects of the combination of dexamethasone and fibroblast growth factor‑2 on differentiation of osteoprecursor cells

Park,Jun‑Beom

doi:10.3892/mmr.2013.1811

Effects of the combination of dexamethasone and fibroblast growth factor‑2 on differentiation of osteoprecursor cells

Authors:
- Jun‑Beom Park
View Affiliations

Affiliations: Department of Periodontics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137‑701, Republic of Korea
Published online on: November 19, 2013 https://doi.org/10.3892/mmr.2013.1811
Pages: 659-662

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dexamethasone is a potent modulator of osteogenic differentiation and previous studies have shown that dexamethasone increases the bone formation capacity of osteoprogenitor cells in vitro. Fibroblast growth factor‑2 (FGF‑2) is reported to have numerous biological activities, including stimulation of cell growth, migration, angiogenesis, wound healing, tissue repair, differentiation and morphogenesis. In the present study, the dose‑dependent effect of dexamethasone and FGF‑2 on the differentiation of osteoprecursor cells was evaluated. The alkaline phosphatase (ALP) activity test was performed to assess differentiation and protein expression associated with bone formation was measured by western blot analysis. The results showed that the protein content of the cultures grown with the osteogenic differentiation media in the presence of 2 ng/ml FGF‑2 was increased compared with that of the untreated control. ALP activity was increased when cells were treated with dexamethasone, with the highest value at 100 nM. The addition of 20 ng/ml FGF‑2 to 100 nM dexamethasone showed an increase in ALP activity, however, this was not statistically significant. The combination of 100 nM dexamethasone and 20 ng/ml FGF‑2 produced the highest expression of bone morphogenetic protein receptor‑IA and bone morphogenetic protein receptor‑II, leading to the highest value of pSmad1/5/8 expression. Within the limits of this study, dexamethasone significantly enhanced osteoblast differentiation, however, the combined delivery of dexamethasone and FGF‑2 did not produce synergistic effects on osteoblast differentiation under the current experimental conditions.

View Figures

View References

1	Naik PN, Chimatadar SA and Nandibewoor ST: Interaction between a potent corticosteroid drug - dexamethasone with bovine serum albumin and human serum albumin: a fluorescence quenching and fourier transformation infrared spectroscopy study. J Photochem Photobiol B. 100:147–159. 2010. View Article : Google Scholar
2	Ishida Y and Heersche JN: Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res. 13:1822–1826. 1998. View Article : Google Scholar
3	Atmani H, Chappard D and Basle MF: Proliferation and differentiation of osteoblasts and adipocytes in rat bone marrow stromal cell cultures: effects of dexamethasone and calcitriol. J Cell Biochem. 89:364–372. 2003. View Article : Google Scholar : PubMed/NCBI
4	Coelho MJ and Fernandes MH: Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation. Biomaterials. 21:1095–1102. 2000. View Article : Google Scholar : PubMed/NCBI
5	Hakki SS, Nohutcu RM, Hakki EE, Berry JE, Akkaya MS and Somerman MJ: Dexamethasone and basic-fibroblast growth factor regulate markers of mineralization in cementoblasts in vitro. J Periodontol. 76:1550–1558. 2005. View Article : Google Scholar : PubMed/NCBI
6	Mansukhani A, Bellosta P, Sahni M and Basilico C: Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol. 149:1297–1308. 2000. View Article : Google Scholar
7	Xiao G, Jiang D, Gopalakrishnan R and Franceschi RT: Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J Biol Chem. 277:36181–36187. 2002. View Article : Google Scholar : PubMed/NCBI
8	Sobue T, Naganawa T, Xiao L, et al: Over-expression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. J Cell Biochem. 95:83–94. 2005. View Article : Google Scholar : PubMed/NCBI
9	Kotev-Emeth S, Pitaru S, Pri-Chen S and Savion N: Establishment of a rat long-term culture expressing the osteogenic phenotype: dependence on dexamethasone and FGF-2. Connect Tissue Res. 43:606–612. 2002. View Article : Google Scholar
10	Lee SY, Lim J, Khang G, et al: Enhanced ex vivo expansion of human adipose tissue-derived mesenchymal stromal cells by fibroblast growth factor-2 and dexamethasone. Tissue Eng Part A. 15:2491–2499. 2009. View Article : Google Scholar : PubMed/NCBI
11	Park JB: Low dose of doxycyline promotes early differentiation of preosteoblasts by partially regulating the expression of estrogen receptors. J Surg Res. 178:737–742. 2012. View Article : Google Scholar : PubMed/NCBI
12	Park JB: The effects of dexamethasone, ascorbic acid, and β-glycerophosphate on osteoblastic differentiation by regulating estrogen receptor and osteopontin expression. J Surg Res. 173:99–104. 2012.
13	Park JB: Combination of simvastatin and bone morphogenetic protein-2 enhances differentiation of osteoblastic cells by regulating the expressions of phospho-Smad1/5/8. Exp Ther Med. 4:303–306. 2012.PubMed/NCBI
14	Park JB: Effects of fibroblast growth factor 2 on osteoblastic proliferation and differentiation by regulating bone morphogenetic protein receptor expression. J Craniofac Surg. 22:1880–1882. 2011. View Article : Google Scholar : PubMed/NCBI
15	Park JB: Effects of doxycycline, minocycline, and tetracycline on cell proliferation, differentiation, and protein expression in osteoprecursor cells. J Craniofac Surg. 22:1839–1842. 2011. View Article : Google Scholar : PubMed/NCBI
16	Beloti MM and Rosa AL: Osteoblast differentiation of human bone marrow cells under continuous and discontinuous treatment with dexamethasone. Braz Dent J. 16:156–161. 2005. View Article : Google Scholar : PubMed/NCBI
17	Fakhry A, Ratisoontorn C, Vedhachalam C, et al: Effects of FGF-2/−9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone. 36:254–266. 2005.
18	Nakamura Y, Wakitani S, Nakayama J, Wakabayashi S, Horiuchi H and Takaoka K: Temporal and spatial expression profiles of BMP receptors and noggin during BMP-2-induced ectopic bone formation. J Bone Miner Res. 18:1854–1862. 2003. View Article : Google Scholar : PubMed/NCBI
19	Kim CH, Cheng SL and Kim GS: Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss. J Endocrinol. 162:371–379. 1999. View Article : Google Scholar